Fresenius SE & Co. KGaA (FRA:FREA)
Germany · Delayed Price · Currency is EUR | Market Cap | 24.92B +5.3% |
| Revenue (ttm) | 22.99B +3.0% |
| Net Income | 1.47B +248.3% |
| EPS | 2.61 +248.3% |
| Shares Out | n/a |
| PE Ratio | 16.95 |
| Forward PE | 12.03 |
| Dividend | 0.17 (1.69%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | n/a |
| Open | 10.70 |
| Previous Close | 10.60 |
| Day's Range | 10.70 - 10.70 |
| 52-Week Range | 8.60 - 20.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod... [Read more]
Financial Performance
In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.
Financial StatementsNews
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
BAD HOMBURG, Germany, July 23, 2026 /PRNewswire/ -- The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its ...
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan
Shares in several European and Asian makers of generic medicines fell after President Trump said the U.S. would place tariffs on such drugs starting in August 2028.
Fresenius SE price target raised to EUR 49 from EUR 48 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on Fresenius SE (FSNUY) to EUR 49 from EUR 48 and keeps an Overweight rating on the shares. Published first…
Fresenius Backs Annual Adj. Earnings Growth Outlook
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius (FSNPF.PK, FSNUF.PK, FRE.DE), a German healthcare company, on Monday reaffirmed its annual adjusted earnings growth guidance.For fiscal 2026, exclud...
Fresenius SE price target lowered to EUR 48 from EUR 56 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 48 from EUR 56 and keeps an Overweight rating on the shares. Published first…
Fresenius SE & Co. KGaA Slides: Credit presentation
Fresenius SE & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% organic revenue and 13% core EPS growth, with strong contributions from Kabi and Helios. Balance sheet strength improved, S&P upgraded the credit outlook, and full-year guidance was reconfirmed amid ongoing geopolitical and regulatory uncertainty.
Fresenius SE & Co. KGaA Slides: Q1 2026
Fresenius SE & Co. KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Fresenius SE & Co. KGaA Earnings release: Q1 2026
Fresenius SE & Co. KGaA released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Quarterly report: Q1 2026
Fresenius SE & Co. KGaA has published its Q1 2026 quarterly earnings report on May 6, 2026.
Fresenius SE price target lowered to EUR 53 from EUR 57 at Citi
Citi lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 53 from EUR 57 and keeps a Buy rating on the shares.
Fresenius SE price target lowered to EUR 56 from EUR 58 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 56 from EUR 58 and keeps an Overweight rating on the shares. Published first…
Fresenius SE & Co. KGaA Slides: Credit presentation
Fresenius SE & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Fresenius SE price target raised to EUR 56.60 from EUR 53.60 at JPMorgan
JPMorgan raised the firm’s price target on Fresenius SE (FSNUY) to EUR 56.60 from EUR 53.60 and keeps an Overweight rating on the shares.
Fresenius SE price target raised to EUR 57 from EUR 56 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs raised the firm’s price target on Fresenius SE (FSNUY) to EUR 57 from EUR 56 and keeps a Buy rating on the shares. Published first…
Fresenius SE price target raised to EUR 58 from EUR 56 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on Fresenius SE (FSNUY) to EUR 58 from EUR 56 and keeps an Overweight rating on the shares. Published first…
Fresenius SE & Co. KGaA Earnings Call Transcript: Q4 2025
Strong 2025 results featured 7% organic revenue and double-digit core EPS growth, with robust Q4 performance and improved leverage. 2026 guidance targets 4%-7% organic revenue growth and 5%-10% core EPS growth, supported by innovation, digitalization, and disciplined capital allocation.
Fresenius SE & Co. KGaA Shareholder letter: Q4 2025
Fresenius SE & Co. KGaA has published a letter to shareholders covering Q4 2025, which was released on February 25, 2026.
Fresenius SE & Co. KGaA Annual report: Q4 2025
Fresenius SE & Co. KGaA has published its Q4 2025 annual report on February 25, 2026.
Fresenius SE & Co. KGaA Annual report: Q4 2025
Fresenius SE & Co. KGaA has published its Q4 2025 annual report on February 25, 2026.
Fresenius SE & Co. KGaA Earnings release: Q4 2025
Fresenius SE & Co. KGaA released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Slides: Q4 2025
Fresenius SE & Co. KGaA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Fresenius SE price target raised to EUR 57 from EUR 52 at Citi
Citi raised the firm’s price target on Fresenius SE (FSNUY) to EUR 57 from EUR 52 and keeps a Buy rating on the shares.
Fresenius SE price target lowered to EUR 56 from EUR 57 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 56 from EUR 57 and keeps an Overweight rating on the shares.
Fresenius SE & Co. KGaA Transcript: 44th Annual J.P. Morgan Healthcare Conference
Healthcare trends and portfolio focus have driven growth, with streamlined operations, innovation, and disciplined capital allocation improving margins and returns. Key segments like IV generics, nutrition, MedTech, and biosimilars are positioned for further expansion, while regulatory and market shifts are being navigated through targeted investment and digitalization.